Skip to main content
. 2024 Feb 12;14:1258991. doi: 10.3389/fonc.2024.1258991

Table 4.

The effects of targeted NSCLC therapies on QT interval (42).

Targeted Therapy Odds of QT Prolongation 99% CI
ALK inhibitors vs. EGFR/BRAF inhibitors combined ROR 5.16 3.92 – 6.81
Crizotinib vs. other ALK inhibitors ROR 1.91 1.22 – 3.00
Ceritinib vs. other targeted NSCLC therapies ROR 3.43 2.02 – 5.81